• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Gelatin, Soft Capsule Gelatin, Hard Capsule Gelatin, Pharmaceutical Gelatin-Foodmate
Neohesperidin
Advantame
Cleanroom Bench Horizontal Laminar Flow Hood Airflow Clean Bench
Pharma and Food Grade, USP/FCC Neotame Sweetener E961
Trilobatin

Sinovac's COVID-19 vaccine 58.5% effective in preventing illness -Chile real world study

firstwordpharmaAugust 04, 2021

Tag: Sinovac , COVID-19 , Vaccine

Chilean health authorities said on Tuesday that Sinovac's COVID-19 vaccine was 58.5% effective in preventing symptomatic infection among millions of Chileans who received it between February and July, as reported This is Money

Sinovac's COVID-19 vaccine 58.5% effective in preventing illness -Chile real world study

Coronavac was 86% effective in preventing hospitalisation, 89.7% effective in preventing intensive care unit admission and 86% effective in preventing deaths within the population, said health official Rafael Araos.


Previous:Tenaya Therapeutics Announces Closing of Upsized Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares

Next:Rupture Disc Market in Industrial Machinery Industry | COVID-19 Impact & Recovery Analysis | Technavio

Related News

Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY

Everest Medicines LimitedDecember 20, 2024

Everest Medicines announced NMPA acceptance of NDA for VELSIPITY(R) (etrasimod) to treat moderately to severely active UC.

Manulife Hong Kong Partners with New Frontier Group to Enhance Cross-Border Healthcare Services

PRNewswireDecember 12, 2024

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer

PRNewswireDecember 12, 2024

Sinovac's COVID-19 vaccine 58.5% effective in preventing illness -Chile real world study | Pharmasources.com

Core8 Group and MedArmor to Pioneer Vietnam's First AI x ESG Hospital

PRNewswireDecember 12, 2024

Core8 Group, an Australian leader in high-tech and biotech innovation, has unveiled plans to develop Vietnam's first AI x ESG Hospital, marking a significant milestone in healthcare transformation.

You may like
More>>

Influenza Vaccine, Live, Nasal, Freeze-dried

Influenza Vaccine, Live, Nasal, Freeze-dried
Polyvalent Pneumococcal Polysaccharide Vaccine

Polyvalent Pneumococcal Polysaccharide Vaccine
Group ACYW135 Meningococcal Polysaccharide Vaccine

Group ACYW135 Meningococcal Polysaccharide Vaccine
SARS-CoV-2 (COVID-19) IgM/IgG ANTIBODY FAST DETECTION KIT (COLLOIDAL GOLD)

SARS-CoV-2 (COVID-19) IgM/IgG ANTIBODY FAST DETECTION KIT (COLLOIDAL GOLD)
vaccine bioreactor system

vaccine bioreactor system
Varicella Vaccine,Live (Vial)

Varicella Vaccine,Live (Vial)
Eurping GMP Washing and Drying Instrument Applied to Pharmaceutical and Vaccine Production

Eurping GMP Washing and Drying Instrument Applied to Pharmaceutical and Vaccine Production
Vi Polysaccharide Typhoid Vaccine

Vi Polysaccharide Typhoid Vaccine
Hepatitis A (Live) Vaccine, Freeze-Dried

Hepatitis A (Live) Vaccine, Freeze-Dried
Rabies Vaccine(Human Diploid Cell)

Rabies Vaccine(Human Diploid Cell)

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service